TY - JOUR
T1 - Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction
T2 - Results from the POPular Genetics Trial
AU - Claassens, Daniel M F
AU - van Dorst, Pim W M
AU - Vos, Gerrit J A
AU - Bergmeijer, Thomas O
AU - Hermanides, Renicus S
AU - van 't Hof, Arnoud W J
AU - van der Harst, Pim
AU - Barbato, Emanuele
AU - Morisco, Carmine
AU - Tjon Joe Gin, Richard M
AU - Asselbergs, Folkert W
AU - Mosterd, Arend
AU - Herrman, Jean-Paul R
AU - Dewilde, Willem J M
AU - Postma, Maarten J
AU - Deneer, Vera H M
AU - Ten Berg, Jurriën M
AU - Boersma, Cornelis
N1 - Funding Information: This work was supported by ZonMw, a Dutch government agency, as part of its efficiency research program (project 171102022). Spartan Bioscience (Nepean, Ottawa, ON, Canada) provided the Spartan RX system and the reagents used free of charge. Funding Information: Dr. Asselbergs has received grants from the University College London Hospitals National Institute for Health Research Biomedical Research Centre. Dr. van 't Hof has received institutional grants from Medtronic, AstraZeneca, and Sanofi and personal fees from AstraZeneca and Amgen. Dr. Barbato has received personal fees from Boston Scientific, Abbott Vascular, and GE. Dr. Ten Berg has received institutional grants from AstraZeneca and ZonMw and personal fees from AstraZeneca, Daiichi Sankyo, Eli Lilly, the Medicines Company, Accumetrics, Boehringer-Ingelheim, Bayer, BMS, Pfizer, and Ferrer. Dr. Postma has received institutional grants from AstraZeneca, GSK, Pfizer, and Amgen and personal fees from AstraZeneca, Daiichi Sankyo, Boehringer-Ingelheim, Bayer, BMS, Pfizer, GSK, and Roche. Daniel M.F. Claassens, Pim W.M. van Dorst, Gerrit J.A. Vos, Thomas O. Bergmeijer, Renicus S. Hermanides, Pim van der Harst, Carmine Morisco, Richard M. Tjon Joe Gin, Arend Mosterd, Jean-Paul R. Herrman, Willem J.M. Dewilde, Vera H.M. Deneer, and Cornelis Boersma have no conflicts of interest that are directly relevant to the content of this article. Publisher Copyright: © 2021, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
PY - 2022/3
Y1 - 2022/3
N2 - INTRODUCTION: The POPular Genetics trial demonstrated that a CYP2C19 genotype-guided P2Y12 inhibitor strategy reduced bleeding rates compared with standard treatment with ticagrelor or prasugrel without increasing thrombotic event rates after primary percutaneous coronary intervention (PCI).OBJECTIVE: In this analysis, we aimed to evaluate the cost effectiveness of a genotype-guided strategy compared with standard treatment with ticagrelor or prasugrel.METHODS: A 1-year decision tree based on the POPular Genetics trial in combination with a lifelong Markov model was developed to compare costs and quality-adjusted life-years (QALYs) between a genotype-guided and a standard P2Y12 inhibitor strategy in patients with myocardial infarction undergoing primary PCI. The cost-effectiveness analysis was conducted from a Dutch healthcare system perspective. Within-trial survival and utility data were combined with lifetime projections to evaluate lifetime cost effectiveness for a cohort of 1000 patients. Costs and utilities were discounted at 4 and 1.5%, respectively, according to Dutch guidelines for health economic studies. Besides deterministic and probabilistic sensitivity analyses, several scenario analyses were also conducted (different time horizons, different discount rates, equal prices for P2Y12 inhibitors, and equal distribution of thrombotic events between the two strategies).RESULTS: Base-case analysis with a hypothetical cohort of 1000 subjects demonstrated 8.98 QALYs gained and €725,550.69 in cost savings for the genotype-guided strategy (dominant). The deterministic and probabilistic sensitivity analysis confirmed the robustness of the model and the cost-effectiveness results. In scenario analyses, the genotype-guided strategy remained dominant.CONCLUSION: In patients undergoing primary PCI, a CYP2C19 genotype-guided strategy compared with standard treatment with ticagrelor or prasugrel resulted in QALYs gained and cost savings.TRIAL REGISTRATION: Clinicaltrials.gov number: NCT01761786, Netherlands trial register number: NL2872.
AB - INTRODUCTION: The POPular Genetics trial demonstrated that a CYP2C19 genotype-guided P2Y12 inhibitor strategy reduced bleeding rates compared with standard treatment with ticagrelor or prasugrel without increasing thrombotic event rates after primary percutaneous coronary intervention (PCI).OBJECTIVE: In this analysis, we aimed to evaluate the cost effectiveness of a genotype-guided strategy compared with standard treatment with ticagrelor or prasugrel.METHODS: A 1-year decision tree based on the POPular Genetics trial in combination with a lifelong Markov model was developed to compare costs and quality-adjusted life-years (QALYs) between a genotype-guided and a standard P2Y12 inhibitor strategy in patients with myocardial infarction undergoing primary PCI. The cost-effectiveness analysis was conducted from a Dutch healthcare system perspective. Within-trial survival and utility data were combined with lifetime projections to evaluate lifetime cost effectiveness for a cohort of 1000 patients. Costs and utilities were discounted at 4 and 1.5%, respectively, according to Dutch guidelines for health economic studies. Besides deterministic and probabilistic sensitivity analyses, several scenario analyses were also conducted (different time horizons, different discount rates, equal prices for P2Y12 inhibitors, and equal distribution of thrombotic events between the two strategies).RESULTS: Base-case analysis with a hypothetical cohort of 1000 subjects demonstrated 8.98 QALYs gained and €725,550.69 in cost savings for the genotype-guided strategy (dominant). The deterministic and probabilistic sensitivity analysis confirmed the robustness of the model and the cost-effectiveness results. In scenario analyses, the genotype-guided strategy remained dominant.CONCLUSION: In patients undergoing primary PCI, a CYP2C19 genotype-guided strategy compared with standard treatment with ticagrelor or prasugrel resulted in QALYs gained and cost savings.TRIAL REGISTRATION: Clinicaltrials.gov number: NCT01761786, Netherlands trial register number: NL2872.
KW - Acute Coronary Syndrome/therapy
KW - Clinical Trials as Topic
KW - Clopidogrel
KW - Cost-Benefit Analysis
KW - Cytochrome P-450 CYP2C19/genetics
KW - Genotype
KW - Humans
KW - Myocardial Infarction/drug therapy
KW - Percutaneous Coronary Intervention
KW - Platelet Aggregation Inhibitors/therapeutic use
KW - Prasugrel Hydrochloride/therapeutic use
UR - http://www.scopus.com/inward/record.url?scp=85114306519&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s40256-021-00496-4
DO - https://doi.org/10.1007/s40256-021-00496-4
M3 - Article
C2 - 34490590
SN - 1175-3277
VL - 22
SP - 195
EP - 206
JO - American journal of cardiovascular drugs
JF - American journal of cardiovascular drugs
IS - 2
ER -